Brief: Adverum Biotechnologies Presents Visual Acuity And Central Subfield Thickness Analyses For Ivt Injection Of Advm-022
15/07/2022 15:53
July 15 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES PRESENTS BEST-CORRECTED VISUAL
ACUITY
AND CENTRAL SUBFIELD THICKNESS ANALYSES AFTER A SINGLE IVT
INJECTION OF ADVM-022 (IXO-VEC) IN THE OPTIC STUDY IN WET AMD
* ADVERUM BIOTECHNOLOGIES INC - STUDY PARTICIPANTS HAD AN
81%-98%
REDUCTION IN ANNUALIZED ANTI-VEGF INJECTIONS
* ADVERUM BIOTECHNOLOGIES INC - STUDY PARTICIPANTS
DEMONSTRATED
CONTINUOUS AFLIBERCEPT EXPRESSION LEVELS THROUGH THREE YEARS
* ADVERUM BIOTECHNOLOGIES INC - PHASE 2 LUNA TRIAL IS
EXPECTED TO
DOSE FIRST SUBJECT IN Q3 OF 2022 AND PRELIMINARY DATA
ANTICIPATED THROUGHOUT 2023
Source text for Eikon: ID:nGNX9hjVhf
Further company coverage: ADVM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)